FRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Fresh Tracks Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. Fresh Tracks Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $0.00 Mil. Therefore, Fresh Tracks Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was N/A%.
The historical data trend for Fresh Tracks Therapeutics's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresh Tracks Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 1,388.08 | - | 23.79 | 15.25 | 10.20 |
Fresh Tracks Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 35.82 | 31.17 | 34.04 | - | - |
For the Biotechnology subindustry, Fresh Tracks Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Fresh Tracks Therapeutics's Effective Interest Rate on Debt % falls into.
Fresh Tracks Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2022 ) | + | Total Debt (A: Dec. 2023 )) | / count ) |
= | -1 * -0.005 | / | ( (0.049 | + | 0) | / 1 ) |
= | -1 * -0.005 | / | 0.049 | |||
= | 10.20 % |
where
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 0.049 |
= | 0.049 |
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 0 |
= | 0 |
Fresh Tracks Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Sep. 2023 ) | + | Total Debt (Q: Dec. 2023 )) | / count ) |
= | -1 * 0 | / | ( (0 | + | 0) | / 1 ) |
= | -1 * 0 | / | 0 | |||
= | N/A % |
where
Total Debt (Q: Sep. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 0 |
= | 0 |
Total Debt (Q: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 0 |
= | 0 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Fresh Tracks Therapeutics (OTCPK:FRTX) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Monica E. Luchi | officer: Chief Medical Officer | 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
Reginald L Hardy | director, officer: CHAIRMAN OF THE BOARD | |
David R. Mcavoy | officer: General Counsel and CCO | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Deepak Chadha | officer: Chief Research & Dev. Officer | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Vijay B Samant | director | 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Jose Breton | officer: Chief Accounting Officer | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Robert Busard Brown | director, officer: Chief Executive Officer | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Andrew D Sklawer | officer: COO and Secretary | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Dennison T Veru | director | C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024 |
Marchio Albert N Ii | officer: Chief Financial Officer | |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Sanjeev Ahuja | officer: Chief Medical Officer | 121 3RD STREET NW, CARMEL IN 46032 |
Adam Scott Levy | officer: Chief Business Officer | C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301 |
William Ju | director | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
R Michael Carruthers | officer: Chief Financial Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
From GuruFocus
By GlobeNewswire • 12-19-2023
By PurpleRose PurpleRose • 08-11-2022
By Value_Insider Value_Insider • 11-10-2022
By GuruFocus Research • 02-13-2024
By Stock market mentor Stock market mentor • 01-27-2023
By GuruFocus Research • 02-13-2024
By GuruFocus Research • 02-13-2024
By Marketwired • 08-11-2023
By GuruFocus Research • 02-13-2024
By GuruFocus Research • 02-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.